Intimation as per regulation 30 _ Meeting Updates
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India's Board has approved setting up a new production unit at its existing plant in Village Bargodam, Haryana, to manufacture Cloxacillin Sodium, Dicloxacillin Sodium and Flucloxacillin Sodium. Separately, the Board approved expanding a unit originally set up in June 2023 to increase production capacity of Amoxicillin. Combined proposed capacity addition is around 1,600 tonnes per annum, taking total capacity from the current 2,400 TPA — roughly a 67% jump. The existing plant is already operating at near-full utilisation (90% maximum, 77% average), so this expansion is aimed at clearing current demand bottlenecks. Estimated investment is Rs. 15–20 crore, to be funded through internal accruals and/or debt, with commercial production targeted by end of December 2025.
Capacity expansion of this scale can support revenue growth and strengthen the product portfolio, especially since existing units are already running tight on capacity. Funding is largely internal, limiting equity dilution risk. Shareholders should watch for timely commissioning by year-end and any further capex or debt disclosures.